JP2020519298A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519298A5
JP2020519298A5 JP2019563082A JP2019563082A JP2020519298A5 JP 2020519298 A5 JP2020519298 A5 JP 2020519298A5 JP 2019563082 A JP2019563082 A JP 2019563082A JP 2019563082 A JP2019563082 A JP 2019563082A JP 2020519298 A5 JP2020519298 A5 JP 2020519298A5
Authority
JP
Japan
Prior art keywords
car
construct
domain
seq
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563082A
Other languages
English (en)
Other versions
JP2020519298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032809 external-priority patent/WO2018213337A1/en
Publication of JP2020519298A publication Critical patent/JP2020519298A/ja
Publication of JP2020519298A5 publication Critical patent/JP2020519298A5/ja
Pending legal-status Critical Current

Links

Claims (17)

  1. (a)切断可能なドメイン;
    (b)第一の抗原結合ドメイン、
    第一の膜貫通ドメイン、及び
    第一の細胞内T細胞シグナル伝達ドメイン
    を含む第一のCAR;並びに
    (c)第二の抗原結合ドメイン、
    第二の膜貫通ドメイン、及び
    第二の細胞内T細胞シグナル伝達ドメイン
    を含む第二のCAR;
    を含む、キメラ抗原受容体(CAR)アミノ酸コンストラクトであって、
    第一及び第二のCARが、切断可能なドメインを介して連結され、
    (i)第一の抗原結合ドメインが、配列番号4、6、及び8の重鎖可変領域CDR配列、並びに配列番号12、14、及び16の軽鎖可変領域CDR配列を含み、且つ
    第一のCARがコンストラクトから切断される場合、第一の抗原結合ドメインはCD22に対する抗原特異性を有するか;または、
    (ii)第一の抗原結合ドメインが、配列番号24、26、及び28の軽鎖可変領域CDR配列、並びに配列番号32、34、及び36の重鎖可変領域CDR配列を含み、且つ
    第一のCARがコンストラクトから切断される場合、第一の抗原結合ドメインはCD19に対する抗原特異性を有する、コンストラクト。
  2. 第一の抗原結合ドメインが配列番号4、6、及び8の重鎖可変領域CDR配列、並びに配列番号12、14、及び16の軽鎖可変領域CDR配列を含む、請求項1に記載のCARコンストラクト。
  3. の抗原結合ドメインが配列番号24、26、及び28の軽鎖可変領域CDR配列、並びに配列番号32、34、及び36の重鎖可変領域CDR配列のアミノ酸配列を含む、請求項1に記載のCARコンストラクト。
  4. の抗原結合ドメインが、配列番号24、26、及び28鎖可変領域CDR配列並びに配列番号32、34、及び36鎖可変領域CDR配列を含む、請求項に記載のCARコンストラクト。
  5. 切断可能なドメインが2A又はフューリンである、請求項1〜のいずれか1項に記載のCARコンストラクト。
  6. 切断可能なドメインが2A及びフューリンである、請求項1〜4のいずれか1項に記載のCARコンストラクト。
  7. CARコンストラクトが、それぞれ第一及び第二のCARである、ちょうど2つのCARを含む、請求項1〜のいずれか1項に記載のCARコンストラクト。
  8. CARが、配列番号48、49、50、51、若しくは52のアミノ酸配列、又は配列番号63〜70のいずれか1と90%以上の配列同一性を有するアミノ酸配列を含む、請求項1に記載のCARコンストラクト。
  9. CARが、配列番号49のアミノ酸配列を含む、請求項1に記載のCAR。
  10. (a)2以上の切断可能なドメイン;
    (b)第一の抗原結合ドメイン、
    第一の膜貫通ドメイン、及び
    第一の細胞内T細胞シグナル伝達ドメイン
    を含む第一のCAR;並びに
    (c)第二の抗原結合ドメイン、
    第二の膜貫通ドメイン、及び
    第二の細胞内T細胞シグナル伝達ドメイン
    を含む第二のCAR;
    を含む、キメラ抗原受容体(CAR)アミノ酸コンストラクトであって、
    第一及び第二のCARが、2以上の切断可能なドメインを介して連結される、コンストラクト。
  11. ちょうど2つの切断可能なドメインが存在する、請求項10のCARコンストラクト。
  12. 請求項1〜11のいずれか1項のCARアミノ酸コンストラクトをコードするヌクレオチド配列を含む、核酸。
  13. 請求項12核酸を含む組換え発現ベクターを含む、単離された宿主細胞。
  14. 請求項1〜11のいずれか1項のCARコンストラクト、請求項12の核酸、請求項13の宿主細胞又の細胞集団と、医薬的に許容される担体とを含む、医薬組成物。
  15. 哺乳動物における、がんの治療ための医薬組成物であって、請求項1〜11のいずれか1項のCARコンストラクト、請求項12の核酸、請求項13の宿主細胞若しくはその細胞集団、又は請求項14の医薬組成物を有効成分として含む、医薬組成物
  16. 前記がんが、血液悪性腫瘍である、請求項15の医薬組成物
  17. キメラ抗原受容体(CAR)アミノ酸コンストラクトの作製方法であって、
    (a)第一の抗原結合ドメイン、
    第一の膜貫通ドメイン、及び
    第一の細胞内T細胞シグナル伝達ドメイン
    を含む第一のCAR;並びに
    (b)第二の抗原結合ドメイン、
    第二の膜貫通ドメイン、及び
    第二の細胞内T細胞シグナル伝達ドメイン
    を含む第二のCAR
    の間に2以上の切断可能なドメインを設計し、第一及び第二のCARが該2以上の切断可能なドメインを介して連結されること;そして
    第一のCAR、2以上の切断可能なドメイン、及び第二のCARを、N末端からC末端までに含む配列を、プラスミドにクローニングすること
    を含む、方法。
JP2019563082A 2017-05-15 2018-05-15 バイシストロン性キメラ抗原受容体及びそれらの使用 Pending JP2020519298A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506268P 2017-05-15 2017-05-15
US62/506,268 2017-05-15
PCT/US2018/032809 WO2018213337A1 (en) 2017-05-15 2018-05-15 Bicistronic chimeric antigen receptors and their uses

Publications (2)

Publication Number Publication Date
JP2020519298A JP2020519298A (ja) 2020-07-02
JP2020519298A5 true JP2020519298A5 (ja) 2021-07-26

Family

ID=62685125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563082A Pending JP2020519298A (ja) 2017-05-15 2018-05-15 バイシストロン性キメラ抗原受容体及びそれらの使用

Country Status (8)

Country Link
US (1) US11980640B2 (ja)
EP (1) EP3625261A1 (ja)
JP (1) JP2020519298A (ja)
KR (1) KR20200005655A (ja)
CN (1) CN110650975B (ja)
AU (1) AU2018269194A1 (ja)
CA (1) CA3062433A1 (ja)
WO (1) WO2018213337A1 (ja)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201609960QA (en) * 2014-06-02 2016-12-29 Us Health Chimeric antigen receptors targeting cd-19
WO2016149578A1 (en) 2015-03-19 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
CA3062433A1 (en) 2017-05-15 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
IT201800003464A1 (it) * 2018-03-13 2019-09-13 Ospedale Pediatrico Bambino Gesu Cellule T CAR-CD30 per il trattamento di tumori CD30+
WO2020069409A1 (en) * 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
KR20210102941A (ko) 2018-12-12 2021-08-20 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
CN113490510A (zh) 2019-01-08 2021-10-08 美国政府(由卫生和人类服务部的部长所代表) 用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体
AU2020212534A1 (en) 2019-01-22 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN113874391A (zh) * 2019-02-20 2021-12-31 希望之城公司 靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途
CA3136618A1 (en) * 2019-04-10 2020-10-15 Elevatebio Technologies, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
GB201906283D0 (en) * 2019-05-03 2019-06-19 Moredun Res Institute Vector
EP3966236A4 (en) * 2019-05-07 2023-05-10 The Board of Trustees of the Leland Stanford Junior University IMPROVEMENT OF POLYPEPTIDES AND CHIMERA ANTIGEN RECEPTORS ACROSS HINGE DOMAINS
CA3142159A1 (en) * 2019-05-31 2020-12-03 City Of Hope Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies
CN112390891B (zh) * 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
EP4031250A1 (en) 2019-10-22 2022-07-27 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
CN115427439A (zh) * 2019-10-30 2022-12-02 德克萨斯A&M大学系统 用于双靶标嵌合抗原受体t细胞疗法的蛋白酶开关
WO2021108613A1 (en) * 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
WO2021168000A1 (en) * 2020-02-17 2021-08-26 University Of Virginia Patent Foundation CAR T CELLS TARGETING THE INTEGRIN ALPHAv BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES
CN113493517B (zh) * 2020-04-02 2023-05-02 重庆精准生物技术有限公司 双特异性单链抗体及其构建的嵌合抗原受体和应用
CN113493516A (zh) * 2020-04-02 2021-10-12 重庆精准生物技术有限公司 靶向双特异性位点的嵌合抗原受体及其应用
CN111632135A (zh) * 2020-05-09 2020-09-08 深圳宾德生物技术有限公司 靶向nkg2d的嵌合抗原受体t细胞在治疗前列腺癌中的应用、治疗前列腺癌的药物
CA3171101A1 (en) * 2020-06-22 2021-12-30 Dina SCHNEIDER Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4271404A2 (en) 2020-12-31 2023-11-08 Sana Biotechnology, Inc. Methods and compositions for modulating car-t activity
EP4274901A1 (en) 2021-01-11 2023-11-15 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
CN112961245B (zh) * 2021-02-24 2023-07-25 重庆精准生物技术有限公司 一种靶向cd96的双特异性抗体及其制备方法和用途
US20240218055A1 (en) 2021-04-29 2024-07-04 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
BR112023024231A2 (pt) 2021-05-19 2024-01-30 Sana Biotechnology Inc Células t primárias rhd negativas hipoimunogênicas
EP4347797A1 (en) 2021-05-27 2024-04-10 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
US20240270851A1 (en) 2021-06-09 2024-08-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
AU2022309875A1 (en) 2021-07-14 2024-01-25 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向cd4之病毒載體之用途
WO2023019203A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
EP4384193A2 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
EP4384189A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
KR20240099402A (ko) 2021-11-09 2024-06-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 글리피칸-3(gpc3)을 표적으로 하는 igg4 힌지-포함 키메라 항원 수용체 및 이의 용도
TW202342757A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科附著醣蛋白
WO2023115039A2 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
CN114478803B (zh) * 2022-02-11 2023-09-26 北京大学深圳研究生院 一种新型双特异性嵌合抗原受体的构建及其应用
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023158986A1 (en) 2022-02-15 2023-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof
IL315000A (en) 2022-02-17 2024-10-01 Sana Biotechnology Inc Transgenic CD47 proteins and their uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024097311A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Hypoimmunogenic mail cells, methods of making and methods of using same
WO2024098038A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Polynucleotide construct and related viral vectors and methods
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
EP3214091B1 (en) 2010-12-09 2018-10-03 The Trustees of The University of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN109485730A (zh) 2011-10-20 2019-03-19 美国卫生和人力服务部 抗cd22嵌合抗原受体
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
AU2013335180B2 (en) 2012-10-24 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
MX2016008076A (es) * 2013-12-19 2016-08-12 Novartis Ag Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
LT3149031T (lt) * 2014-05-29 2020-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T ląstelių receptoriai prieš žmogaus papilomos virusą 16 e7
SG11201609960QA (en) 2014-06-02 2016-12-29 Us Health Chimeric antigen receptors targeting cd-19
AU2015292755B2 (en) * 2014-07-21 2020-11-12 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
RU2022102250A (ru) * 2014-12-24 2022-03-23 Отолус Лимитед Клетка
WO2016149578A1 (en) * 2015-03-19 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
SG10201913682QA (en) 2015-06-25 2020-03-30 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
CN105647873A (zh) * 2016-03-14 2016-06-08 紫程瑞生会(北京)生物技术发展有限公司 一种双特异性嵌合抗原受体基因修饰的自然杀伤细胞的制备方法及其试剂盒
CA3062433A1 (en) 2017-05-15 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
US10822412B2 (en) 2018-09-26 2020-11-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy

Similar Documents

Publication Publication Date Title
JP2020519298A5 (ja)
JP2019514361A5 (ja)
JP2022109953A5 (ja)
ES2773527T3 (es) Receptor quimérico para antígeno
JP2013509879A5 (ja)
JP2016502512A5 (ja)
JP2018531014A5 (ja)
JP2019535262A5 (ja)
JP2019521643A5 (ja)
JP2018529380A5 (ja)
RU2015122484A (ru) Агенты для лечения экспрессирующих клаудин раковых заболеваний
CA2561826A1 (en) Linear single chain recombinant anti-cea/cd3/cd28 trispecific antibody
JP2018537087A5 (ja)
JP2017537627A5 (ja)
JP2013502226A5 (ja)
JP2020500015A5 (ja)
JP2018523484A (ja) 細胞
JP2010273685A5 (ja)
JP2018536431A5 (ja)
JP2019506166A5 (ja)
JP2012025766A5 (ja)
JP2012025737A5 (ja)
JP2018501794A5 (ja)
JP2008504012A5 (ja)
JP2018505139A5 (ja)